drugset / Trial / NCT06519565
Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)
Phase 0
Recruiting
6 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shenzhen Pregene Biopharma Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, open-label, 3+3 dose escalation, early phase 1 study to evaluate the safety, tolerability, and preliminary efficacy of PRG-1801 for patients with relapsed/refractory immune thrombocytopenia (ITP).
Timeline
- Start
- 2024-08-20
- Primary completion
- 2026-12-15
- Completion
- 2027-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRG-1801 | Cell therapy | 1e+08 cells | Intravenous |
| Subject | PRG-1801 | Cell therapy | 2e+08 cells | Intravenous |